Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
Biologics
Crohn’s disease
Elderly
Inflammatory bowel diseases
Ustekinumab
Vedolizumab
Journal
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
ISSN: 0975-0711
Titre abrégé: Indian J Gastroenterol
Pays: India
ID NLM: 8409436
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
31
03
2022
accepted:
09
05
2023
medline:
27
9
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn's disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.
Identifiants
pubmed: 37523059
doi: 10.1007/s12664-023-01391-3
pii: 10.1007/s12664-023-01391-3
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
vedolizumab
9RV78Q2002
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
718-723Informations de copyright
© 2023. Indian Society of Gastroenterology.
Références
Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: Three-year efficacy, safety, and immunogenicity of Ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2020;14:23–32.
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.
Panaccione R, Danese S, Sandborn WJ, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020;52:1658–75.
doi: 10.1111/apt.16119
pubmed: 33086438
pmcid: 8776399
Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: Results from the US VICTORY Consortium. Am J Gastroenterol. 2016;111:1147–55.
Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.
doi: 10.1007/s10620-012-2083-x
pubmed: 22359191
Garg R, Aggarwal M, Butler R, et al. Real-world effectiveness and safety of Ustekinumab in elderly Crohn’s disease patients. Dig Dis Sci. 2022;67:3138–47.
LeBlanc JF, Wiseman D, Lakatos PL, et al. Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape. World J Gastroenterol. 2019;25:4158–71.
doi: 10.3748/wjg.v25.i30.4158
pubmed: 31435170
pmcid: 6700701
Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32.
doi: 10.1136/gutjnl-2012-303864
pubmed: 23408350
Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11:263–73.
Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52:669–81.
doi: 10.1111/apt.15921
pubmed: 32656800
pmcid: 7496810
Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: Treatment outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018;113:1345.
Cohen NA, Plevris N, Kopylov U, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterol J. 2020;8:1076–85.
doi: 10.1177/2050640620951400
pubmed: 32807038
pmcid: 7724539
Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep (Oxf). 2020;8:306–11.
Biemans VBC, van der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52:123–34.
doi: 10.1111/apt.15745
pubmed: 32441396
pmcid: 7318204
Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease. Aliment Pharmacol Ther. 2020;52:1341–52.
doi: 10.1111/apt.16057
pubmed: 32955122
Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor alpha antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49:873–9.
doi: 10.1111/apt.15177
pubmed: 30773667
pmcid: 6423511
Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: Phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10:1224–36.
Geisz M, Ha C, Kappelman MD, et al. Medication utilization and the impact of continued corticosteroid use on patient-reported outcomes in older patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1435–41.
Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160:2496–508.
Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: Management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.
Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment. J Crohns Colitis. 2020;14:4–22.